Atossa Therapeutics, Inc.

Report final Phase 2 data for McCune-Albright Syndrome

Deadline not yet reached (246 days left)

Announced: 18 Sep 2026
Due: 30 Jun 2027

Deadline
Met
Late
Not met
Today

What the company said

“Final Ph2 data anticipated in 1H27”

SourceAtossa Therapeutics, Inc. Form 8-K press release, 2026-09-18
FilingSEC filing index
Deadline as stated1H27
Deadline used30 Jun 2027, the last day of the stated period
TypeProject
Permanent referenceKI-C-2026-ATOS-000812
Cite as https://keptindex.org/c/KI-C-2026-ATOS-000812/ — this address never changes.

What we found

The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 30 Jun 2027.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout
Indicative materiality: Medium rules
Action: Report
Language: Expected (“expects”, “plans”)

Tell me what happens

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Alert me when this resolves

How this entry was checked

Commitment recordedRecorded from the company's filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Atossa Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2026-ATOS-000812 · Corrections policy